Singapore April 2025 – ChemT Biotechnology Co-Founders Ms. Jie Sun and Dr. Ling Wu joined industry leaders John Ng of Dark Horse Consulting, Sen (Sean) Lin of ChemLex, and Dr. Qiusong Tang of Roche in an April 2025 panel on the future of artificial intelligence in drug discovery and biologics manufacturing. The discussion addressed AI’s potential to accelerate early-stage discovery, optimize bioprocessing, and improve quality control in cell and gene therapies, while emphasizing the need for human expertise to validate AI-generated insights.

Panelists also explored regulatory considerations, including the FDA’s call for transparency, validation, and bias mitigation in AI-driven drug development. Looking ahead, they forecast AI’s expanding role over the next decade in manufacturing, clinical trials, and regulatory submissions, with AI-powered automation poised to make personalized cell therapies more scalable and cost-effective.